Accessibility Menu
Adherium logo

Adherium(ASX) ADR

Market CapA$6.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2015)-100%
5 Year-100%
1 Year-80%
1 Month-9%
A$0.10
-9.09%
-0.01Today
Adherium last closing stock price
MetricPriceDate
Last closeAUD 0.102026-08-14
Adherium stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.102026-08-04
1 month-9.09%AUD 0.112026-07-15
3 month-50%AUD 0.202026-05-15
Year to date-80%AUD 0.502025-12-31
1 year-80%AUD 0.502025-08-14
3 year-99.77%AUD 43.502019-06-28
5 year-99.77%AUD 43.502019-06-28
Since inception-99.98%AUD 618.542015-08-26

Adherium Financials at a Glance

Market Cap

A$6.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.08M

Net Income (TTM)

-A$24.09M

EPS (TTM)

-A$1.01

P/E Ratio

-0.11

Dividend

A$0.00

Beta (Volatility)

-2.76 (Low)

Price

A$0.10

Volume

13,130

Open

A$0.11

Previous Close

A$0.10

Daily Range

A$0.10 - A$0.12

52-Week Range

A$0.00 - A$0.80

Estimated Earnings Date

Aug 28, 2026

ADR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adherium

Adherium Limited specializes in developing advanced digital health solutions aimed at enhancing medication adherence for individuals managing chronic conditions. The company operates in key international markets, including New Zealand, Australia, Europe, North America, and Asia, with a focus on chronic respiratory illnesses.

Products and Services
  • Hailie system for optimizing medication use
  • Bluetooth-enabled sensors for inhalers
  • Mobile application and online portal for patient support
Growth Outlook
  • Expansion into new international markets is underway
  • Increased demand for digital health solutions post-pandemic
  • Focus on chronic respiratory diseases presents significant growth potential
Financial Highlights
  • Recent quarterly revenue of AUD 801,402 shows growth from previous quarters
  • Trailing twelve months (TTM) gross profit margin stands at 34.02%
  • Cash and cash equivalents increased to AUD 642,275 in the latest quarter
Adherium Limited is positioned in the healthcare sector, focusing on innovative solutions that address medication adherence challenges. The Hailie system, which integrates technology with patient care, is a cornerstone of the company's offerings. Recent financial data indicates a positive trend in revenue, suggesting a potential recovery and growth trajectory. The company's strategic focus on expanding its market presence and addressing the growing demand for digital health solutions aligns with current healthcare trends, making it an intriguing option for investors interested in the medical devices industry.
AI Generated • Jul 16, 2026

Industry

Health Care Technology

CEO

Jeremy Laurence Curnock-Cook

Headquarters

Melbourne, VIC 3000, AU

ADR Financials

Key Financial Metrics (TTM)

Gross Margin

34.02%

Operating Margin

-1132.33%

Net Income Margin

-1141.40%

Return on Equity

459.94%

Return on Capital

N/A

Return on Assets

-307.04%

Earnings Yield

-9.09%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$6.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

54.89M

Volume

13.13K

Avg. Volume

13.50K

Financials (TTM)

Gross Profit

A$133.52K

Operating Income

-A$25.20M

EBITDA

-A$25.03M

Operating Cash Flow

-A$22.10M

Capital Expenditure

-A$76.46K

Free Cash Flow

-A$22.18M

Cash & ST Invst.

A$642.28K

Total Debt

A$1.33M

Adherium Performance Analysis

Adherium annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-06-30AUD 529,000N/A
20232023-06-30AUD 3,195,000504.0%
20242024-06-30AUD 840,982-73.7%
20252025-06-30AUD 817,237-2.8%
Adherium sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-3023.0%
Q22024-12-317.9%
Q42025-06-30-36.7%
Q22025-12-31152.9%
Adherium annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-06-30AUD -4.76N/A
20232023-06-30AUD -2.48-47.8%
20242024-06-30AUD -1.98-20.2%
20252025-06-30AUD -1.40-29.5%
Adherium sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-304.4%
Q22024-12-3141.5%
Q42025-06-3013.2%
Q22025-12-3162.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$801.40K

+112.5%

Gross Profit

A$554.98K

+613.9%

Gross Margin

69.25%

N/A

Market Cap

A$6.04MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$150.94K

N/A

Employees

40

N/A

Net Income

-A$5.86M

-25.4%

EBITDA

-A$5.98M

-24.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$642.28K

-79.6%

Total Debt

A$1.33M

+6304.5%

Accounts Receivable

A$1.41M

-37.5%

Inventory

A$1.61M

+9.3%

Long Term Debt

A$0.00

N/A

Short Term Debt

A$1.33M

+6304.5%

Return on Assets

-3.07%

N/A

Return on Invested Capital

16.51%

N/A

Free Cash Flow

-A$7.46M

-25.9%

Operating Cash Flow

-A$7.43M

-25.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BGT.AXBio-Gene Technology Limited
A$0.02+0.00%
HIQ.AXHITIQ Limited
A$0.01+0.00%
PER.AXPercheron Therapeutics Limited
A$0.01+11.11%
IVX.AXInvion Limited
A$0.04+2.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
ONDSOndas
$8.91-0.09%
SMCISuper Micro Computer
$39.16+0.04%
SPCXSpace Exploration Technologies
$141.29-0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.64+0.07%

Questions About ADR

What is the current price of Adherium?

Adherium is trading at A$0.10 per share.

What is the 52-week range for Adherium?

Over the past 52 weeks, Adherium has traded between A$0.00 and A$0.80.

How much debt does Adherium have?

As of the most recent reporting period, Adherium reported total debt of A$3.12M.

How much cash does Adherium have on hand?

Adherium reported A$43.26K in cash and cash equivalents in its most recent financial results.

What is Adherium’s dividend yield?

Adherium does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.